Insulet stock is trading -21.04% below its average target price of $312.14 after dropping -1.9% during today's morning session. Analysts are giving the Large-Cap Medical Instruments & Supplies company an average rating of buy and target prices ranging from $234.0 to $350.0 per share.
Insulet's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.5%. The stock's short ratio is 2.7. The company's insiders own 0.38% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 103.0%. In conclusion, we believe there is mixed market sentiment regarding Insulet.
Institutions Invested in Insulet
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-12-31 | Vanguard Group Inc | 12% | 8,489,976 | $2,092,524,395 |
| 2024-12-31 | FMR, LLC | 11% | 7,775,811 | $1,916,504,146 |
| 2024-12-31 | Capital Research Global Investors | 11% | 7,446,305 | $1,835,290,802 |
| 2024-12-31 | Blackrock Inc. | 9% | 6,265,418 | $1,544,237,582 |
| 2024-12-31 | State Street Corporation | 4% | 2,974,463 | $733,115,899 |
| 2024-12-31 | BAILLIE GIFFORD & CO | 3% | 2,355,683 | $580,605,191 |
| 2024-12-31 | Geode Capital Management, LLC | 3% | 1,779,167 | $438,511,292 |
| 2024-12-31 | FIL LTD | 2% | 1,431,307 | $352,774,238 |
| 2024-12-31 | ClearBridge Investments, LLC | 2% | 1,406,353 | $346,623,825 |
| 2024-12-31 | Morgan Stanley | 2% | 1,297,784 | $319,864,824 |
